HSD3B7 and neoplasm: Tumor weight, measured at the end of the 30-day observation period, was significantly lower in the LV-h-HSD3B7 group compared to controls, suggesting that HSD3B7 silencing inhibits tumor growth in vivo (Figure 8C).